NCT04162600 is a Phase 1 clinical trial of ChAdOx2 RabG in Rabies, sponsored by University of Oxford.

Who is sponsoring NCT04162600?

NCT04162600 is sponsored by University of Oxford.

What drugs are being tested in NCT04162600?

Interventions in NCT04162600: ChAdOx2 RabG, Inactivated Rabies Vaccine, ChAdOx2 RabG, ChAdOx2 RabG, Inactivated Rabies Vaccine, Inactivated Rabies Vaccine.

Is NCT04162600 still recruiting?

NCT04162600 is currently terminated. Last updated 8 November 2024.

Last reviewed 2024-11-08 · How we verify

NCT04162600

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG

Terminated Phase 1 Last updated 8 November 2024

What this trial tests

Phase 1 trial testing ChAdOx2 RabG in Rabies in 18 participants. Terminated before completion.

Timeline

2 January 2020

Primary endpoint
10 July 2024

10 July 2024

Quick facts

Lead sponsor	University of Oxford
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	2 January 2020
Primary completion	10 July 2024
Estimated completion	10 July 2024
Sites	1 location across United Kingdom

Drugs / interventions tested

ChAdOx2 RabG — full drug profile →
Inactivated Rabies Vaccine — full drug profile →
ChAdOx2 RabG — full drug profile →
ChAdOx2 RabG — full drug profile →
Inactivated Rabies Vaccine — full drug profile →
Inactivated Rabies Vaccine — full drug profile →

Conditions studied

Rabies — all drugs for Rabies →

Sponsor

University of Oxford

Who can join

Adults 18 to 65, any sex, with Rabies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a first-in-human, open-label, dose escalation, phase I clinical trial to assess the safety and immunogenicity of the candidate ChAdOx2 RabG vaccine in healthy UK volunteers aged 18-65. The vaccine will be administered intramuscularly (IM).

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases.
Wang S, Liang B, Wang W, Li L, et al · · 2023 · cited 124× · PMID 37029123 · DOI 10.1038/s41392-023-01408-5
Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial.
Jenkin D, Ritchie AJ, Aboagye J, Fedosyuk S, et al · · 2022 · cited 20× · PMID 35907430 · DOI 10.1016/s2666-5247(22)00126-4
Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations.
Berg A, Wright D, Dulal P, Stedman A, et al · · 2021 · cited 19× · PMID 34835180 · DOI 10.3390/vaccines9111249

Verify or expand the search:

Other recruiting trials for Rabies

Currently open trials in the same condition.

NCT07275645 — A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried in a Population Aged 10 to 60 Years · Phase 3 · active not recruiting
NCT07021703 — A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried · Phase 1 · recruiting
NCT06998004 — A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for the Prevention of Yellow Fever, and · Phase 1 · recruiting

Other University of Oxford trials

Trials by the same sponsor.

NCT05380388 — A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 ) · Phase 2 · not yet recruiting
NCT07470424 — A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults · Phase 1 · not yet recruiting
NCT07345910 — Environment, Pathogens, and Host Interactions in Melioidosis · not yet recruiting
NCT07434973 — Stratification and Treatment in Early Psychosis Study - PROMOTE · Phase 3 · not yet recruiting
NCT07460401 — 'Do Patient Characteristics Associate With Poor Outcome With Femoral Acetabular Impingement Syndrome (FAIS) Following Ph · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04162600 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Oxford
Last refreshed: 8 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04162600.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing